Kodiak Sciences Inc

Kodiak Sciences Inc

96.80
USD
-3.93
(-3.90%)
-4.08EPS
6.10BMarket Cap
Apr 01Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.65
-1.05
-2.77
-1.25
-2.91
-5.16
-6.39
-4.97
-3.35
-4.32
-4.08
Free Cash Flow per Basic Share
-0.63
-0.67
-1.98
-1.05
-1.98
-4.74
-4.86
-3.73
-2.24
-2.57
-2.86
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.16
-1.94
2.36
7.78
16.84
12.8
8.33
5.06
2.85
2.55
0.2
Tangible Book Value per Share
-1.16
-1.94
2.36
7.78
16.84
12.8
8.33
5.06
2.85
2.55
0.2
Basic Weighted Avg Shares
27
27
15
38
46
52
52
52
53
53
60
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
- -
1
4
9
11
26
27
26
24
Net Income, GAAP
-17
-28
-41
-47
-133
-267
-334
-260
-176
-230
-247
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
8
-8
86
328
941
670
434
248
146
169
38
LT Debt
- -
10
- -
2
75
76
78
72
60
47
41
Total Equity
-41
-69
87
345
861
663
436
266
150
157
13
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-21.92
-22.07
-35.04
-60.72
-74.22
-84.7
-149.49
-1,360.91

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
12
10
5
LT Borrowings
- -
- -
- -
LT Finance Leases
44
43
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
63
64
Market Capitalization
2,369
2,448
6,096

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
175
131
93
Cash, Cash Equivalents & STI
170
126
89
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
50
53
55
Payables & Accruals
38
43
49
ST Debt
12
10
5
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-26.99%
4.72%
Free Cash Flow
- -
25.63%
15.97%
Net Income, GAAP
- -
20.36%
30.51%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.82
-0.86
-0.84
-0.84
-3.35
2025
-1.09
-1.03
-1.16
-1.04
-4.32
2026
-0.94
-1.05
-1.05
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Victor Perlroth
Full Time Employees
124
Sector
Health technology
Industry
Biotechnology
Address
1200 Page Mill Road Palo Alto CA United States 94304
IPO Date
Oct 4, 2018
Website
kodiak.com
Business
Kodiak Sciences Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of innovative treatments for prevalent retinal diseases. The company leverages its proprietary Antibody Biopolymer Conjugate (ABC®) platform to create long-acting therapies. Its lead investigational product, tarcocimab tedromer, an anti-vascular endothelial growth factor (VEGF) agent, has progressed through multiple Phase 3 clinical studies for various retinal vascular conditions, including diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The tarcocimab program was recently re-evaluated and is advancing with ongoing Phase 3 trials, GLOW2 for diabetic retinopathy and DAYBREAK for wet age-related macular degeneration, with topline results anticipated in 2026. Kodiak's pipeline also features KSI-501, a bispecific antibody biopolymer conjugate designed to inhibit both VEGF and interleukin-6 (IL-6) for retinal conditions with an inflammatory component, currently in a Phase 3 study for wet age-related macular degeneration, with topline data expected in 2026. Additionally, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF, has shown promising Phase 1b results for macular edema secondary to inflammation, and is now in two Phase 3 studies, PEAK and PINNACLE, with data expected in late 2026 and early 2027. In preclinical development, KSI-601 is a triplet inhibitor being explored for dry age-related macular degeneration. The company was established in 2009, initially as Oligasis, LLC, adopting the name Kodiak Sciences Inc. in September 2015, and operates from Palo Alto, California.

Company News

  • Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript

  • Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In

  • Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

  • Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results

  • Kodiak Sciences to Present at Three Upcoming Investor Conferences

  • Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review

  • Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

  • Kodiak Sciences Inc. (NASDAQ:KOD) Stock Has Average Target Price of $104.71

  • 11 Stocks Most Likely to See a Short Squeeze Rally

  • Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

  • Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

  • Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock

  • A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

  • KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

  • Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing

  • Why Kodiak Sciences Skyrocketed Today

  • Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

  • Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

  • Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results

  • Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine